1 day chart
Dimerix Limited (DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.
Buy Australian shares starting with DXB. Invest today with a CHESS-sponsored investing platform!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake AUS
- Deposit directly into your Stake wallet and you're ready to invest in DXB
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.